What we do

ANDA

Developing bioequivalent formulations of high barrier to entry products with significant development, legal and regulatory challenges. We are focused on targeting high-value solid oral and alternative dosage form ANDAs that are difficult to develop and that bring sustainable profitability.

Product Pipeline

505(b)(2)

Developing differentiated products by applying our ElectroNanospray (ENS) platform to improve the performance of existing drug products with poor solubility, low bioavailability, high food effect, or variable PK.

Product Pipeline

ENABLING

Enable formulations for preclinical development. Nanocopoeia is a formulation and process resource for the pharmaceutical industry. Nanocopoeia works with drug development companies to create efficient and effective ways to enable formulations of challenging new chemical entities and/or leverage existing libraries of compounds with known solubility issues but potentially significant commercial value.

 

The benefits

  • Drug Performance Improvement

    Improving Drugs

    Improving drugs through nanoformulation of challenging APIs

  • Novel ENS Innovation

    Innovation

    Novel ENS platform
    Uniform, small, amorphous particles

  • Speed to Market Nanoformulation

    Speed to Market

    Nanoformulation prototyping
    Rapid process optimization

  • Nanoformulation IP Opportunity

    IP Opportunity

    New intellectual property Lifecycle management

What we offer